nach oben

Heart Failure Reviews

Erschienen in:

01.07.2013

Iron deficiency anemia in heart failure

verfasst von: Natasha P. Arora, Jalal K. Ghali

Erschienen in: Heart Failure Reviews | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Anemia and iron deficiency are quite prevalent in patients with heart failure (HF) and may overlap. Both anemia and iron deficiency are associated with worse symptoms and adverse clinical outcomes. In the past few years, there has been an enormous interest in the subject of iron deficiency and its management in patients with HF. In this review, the etiology and relevance of iron deficiency, iron metabolism in the setting of HF, studies on iron supplementation in patients with HF and potential cardiovascular effects of subclinical iron overload are discussed.

Lindenfeld J (2005) Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149(3):391–401. doi:10.1016/j.ahj.2004.08.039 PubMedCrossRef

Ghali JK (2009) Anemia and heart failure. Curr Opin Cardiol 24(2):172–178. doi:10.1097/HCO.0b013e328324ecec PubMedCrossRef

WHO (2001) Iron deficiency anaemia: assessment, prevention and control: a guide for programme managers. WHO

Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52(10):818–827. doi:10.1016/j.jacc.2008.04.061 PubMedCrossRef

Zuccala G, Marzetti E, Cesari M, Lo Monaco MR, Antonica L, Cocchi A, Carbonin P, Bernabei R (2005) Correlates of cognitive impairment among patients with heart failure: results of a multicenter survey. Am J Med 118(5):496–502. doi:10.1016/j.amjmed.2005.01.030 PubMedCrossRef

Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780–1786PubMedCrossRef

Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP, Poole-Wilson PA, Coats AJ, Anker SD (2003) Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 91(7):888–891PubMedCrossRef

Salisbury AC, Kosiborod M (2010) Outcomes associated with anemia in patients with heart failure. Heart failure clin 6(3):359–372. doi:10.1016/j.hfc.2010.03.005 CrossRef

Adams KF Jr, Pina IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, Stough WG, Mehra MR, Felker GM, Chiong JR, Patterson JH, Kim J, Butler J, Oren RM (2009) Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 158(6):965–971. doi:10.1016/j.ahj.2009.10.015 PubMedCrossRef

10.

Eschbach JW (2002) Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. J Am Soc Nephrol (JASN) 13(5):1412–1414CrossRef

11.

Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28(2):166–171. doi:10.1093/eurheartj/ehl419 PubMedCrossRef

12.

Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107(2):226–229PubMedCrossRef

13.

Adlbrecht C, Kommata S, Hulsmann M, Szekeres T, Bieglmayer C, Strunk G, Karanikas G, Berger R, Mortl D, Kletter K, Maurer G, Lang IM, Pacher R (2008) Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J 29(19):2343–2350. doi:10.1093/eurheartj/ehn359 PubMedCrossRef

14.

Weiss G, Goodnough LT (2005) Anemia of chronic disease. New Engl J Med 352(10):1011–1023. doi:10.1056/NEJMra041809 PubMedCrossRef

15.

Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45(3):391–399. doi:10.1016/j.jacc.2004.10.038 PubMedCrossRef

16.

van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112(12):1743–1747. doi:10.1161/CIRCULATIONAHA.105.549121 PubMedCrossRef

17.

Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112(8):1121–1127. doi:10.1161/CIRCULATIONAHA.104.512988 PubMedCrossRef

18.

Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA (2006) The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27(12):1440–1446. doi:10.1093/eurheartj/ehl012 PubMedCrossRef

19.

von Haehling S, van Veldhuisen DJ, Roughton M, Babalis D, de Boer RA, Coats AJ, Manzano L, Flather M, Anker SD (2011) Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 13(6):656–663. doi:10.1093/eurjhf/hfr044 CrossRef

20.

Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ, Klinkenberg T, van der Harst P, Vellenga E, van Veldhuisen DJ, van Gilst WH (2010) Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 12(7):676–684. doi:10.1093/eurjhf/hfq061 PubMedCrossRef

21.

Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, Heeschen C, Spyridopoulos I, Dimmeler S, Zeiher AM (2007) Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 49(24):2341–2349. doi:10.1016/j.jacc.2007.01.095 PubMedCrossRef

22.

Okonko DO, Crosato M, Kalra PR, Cicoira M, John M, Doehner W, Coats AJ, Poole-Wilson PA, Anker SD (2005) Association of deranged adrenal steroid metabolism with anemia in chronic heart failure. Am J Cardiol 96(1):101–103. doi:10.1016/j.amjcard.2005.02.053 PubMedCrossRef

23.

van der Meer P, Lok DJ, Januzzi JL, de la Porte PW, Lipsic E, van Wijngaarden J, Voors AA, van Gilst WH, van Veldhuisen DJ (2008) Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29(12):1510–1515. doi:10.1093/eurheartj/ehn205 PubMedCrossRef

24.

Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL (2004) Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147(5):924–930. doi:10.1016/j.ahj.2003.11.007 PubMedCrossRef

25.

Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232–2237. doi:10.1093/eurheartj/ehi388 PubMedCrossRef

26.

Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107(2):223–225PubMedCrossRef

27.

Duffy TP (2004) Microcytic and hypochromic anemias. Cecil Textbook of Medicine, Saunders

28.

de Silva R, Rigby AS, Witte KK, Nikitin NP, Tin L, Goode K, Bhandari S, Clark AL, Cleland JG (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98(3):391–398. doi:10.1016/j.amjcard.2006.01.107 PubMedCrossRef

29.

Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48(12):2485–2489. doi:10.1016/j.jacc.2006.08.034 PubMedCrossRef

30.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. New Engl J Med 361(25):2436–2448. doi:10.1056/NEJMoa0908355 PubMedCrossRef

31.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31(15):1872–1880. doi:10.1093/eurheartj/ehq158 PubMedCrossRef

32.

Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12):1241–1251. doi:10.1016/j.jacc.2011.04.040 PubMedCrossRef

33.

Lee G (1993) Iron deficiency and iron-deficiency anemia. Wintrobe’s clinical haematology. Lea & Febiger, Philadelphia

34.

Zimmermann MB, Hurrell RF (2007) Nutritional iron deficiency. Lancet 370(9586):511–520. doi:10.1016/S0140-6736(07)61235-5 PubMedCrossRef

35.

Weiss G (2009) Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 1790(7):682–693. doi:10.1016/j.bbagen.2008.08.006 PubMedCrossRef

36.

Handelman GJ, Levin NW (2008) Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13(4):393–404. doi:10.1007/s10741-008-9086-x PubMedCrossRef

37.

Cunietti E, Chiari MM, Monti M, Engaddi I, Berlusconi A, Neri MC, De Luca P (2004) Distortion of iron status indices by acute inflammation in older hospitalized patients. Arch Gerontol Geriatr 39(1):35–42. doi:10.1016/j.archger.2003.12.005 PubMedCrossRef

38.

Means RT Jr, Allen J, Sears DA, Schuster SJ (1999) Serum soluble transferrin receptor and the prediction of marrow aspirate iron results in a heterogeneous group of patients. Clin Lab Haematol 21(3):161–167PubMedCrossRef

39.

Cook JD, Skikne BS, Baynes RD (1993) Serum transferrin receptor. Annu Rev Med 44:63–74. doi:10.1146/annurev.me.44.020193.000431 PubMedCrossRef

40.

Beguin Y, Clemons GK, Pootrakul P, Fillet G (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81(4):1067–1076PubMed

41.

Punnonen K, Irjala K, Rajamaki A (1997) Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89(3):1052–1057PubMed

42.

Thomas C, Kirschbaum A, Boehm D, Thomas L (2006) The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol 23(1):23–36. doi:10.1385/MO:23:1:23 PubMedCrossRef

43.

Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48(7):1066–1076PubMed

44.

Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzoska K, Piotrowski W, Rywik TM, Danko B, Polkowska-Motrenko H, Rozanski JM, Kruszewski M (2011) Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol. doi:10.1016/j.ijcard.2011.08.006 PubMed

45.

Naito Y, Tsujino T, Fujimori Y, Sawada H, Akahori H, Hirotani S, Ohyanagi M, Masuyama T (2011) Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens 29(4):741–748. doi:10.1097/HJH.0b013e3283434784 PubMedCrossRef

46.

Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H (2007) The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 148(6):2663–2668. doi:10.1210/en.2006-1331 PubMedCrossRef

47.

Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Akahori H, Sakoda T, Ohyanagi M, Tomosugi N, Masuyama T (2010) Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J Off J Jap Circu Soc 74(2):301–306

48.

Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Nat Acad Sci USA 99(7):4596–4601. doi:10.1073/pnas.072632499 PubMedCrossRef

49.

Ganz T, Nemeth E (2011) Hepcidin and disorders of iron metabolism. Annu Rev Med 62:347–360. doi:10.1146/annurev-med-050109-142444 PubMedCrossRef

50.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704):2090–2093. doi:10.1126/science.1104742 PubMedCrossRef

51.

van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA (2010) Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 12(9):943–950. doi:10.1093/eurjhf/hfq099 PubMedCrossRef

52.

Haas JD, Brownlie Tt (2001) Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 131(2S-2):676S-688S; discussion 688S-690S

53.

Cairo G, Bernuzzi F, Recalcati S (2006) A precious metal: iron, an essential nutrient for all cells. Genes Nutr 1(1):25–39. doi:10.1007/BF02829934 PubMedCrossRef

54.

Anderson GJ, Vulpe CD (2009) Mammalian iron transport. Cell Mol Life Sci (CMLS) 66(20):3241–3261. doi:10.1007/s00018-009-0051-1 CrossRef

55.

Andrews NC (1999) Disorders of iron metabolism. New Engl J Med 341(26):1986–1995. doi:10.1056/NEJM199912233412607 PubMedCrossRef

56.

Sutak R, Lesuisse E, Tachezy J, Richardson DR (2008) Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol 16(6):261–268. doi:10.1016/j.tim.2008.03.005 PubMedCrossRef

57.

Wilson MT, Reeder BJ (2008) Oxygen-binding haem proteins. Exp Physiol 93(1):128–132. doi:10.1113/expphysiol.2007.039735 PubMedCrossRef

58.

Gomollon F, Gisbert JP (2009) Anemia and inflammatory bowel diseases. World J Gastroenterol (WJG) 15(37):4659–4665CrossRef

59.

Anker SD, Sharma R (2002) The syndrome of cardiac cachexia. Int J Cardiol 85(1):51–66PubMedCrossRef

60.

Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J (2005) Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109(3):277–286. doi:10.1042/CS20040278 CrossRef

61.

Katz SD, Zheng H (2002) Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol 9(2):215–225CrossRef

62.

Brownlie Tt, Utermohlen V, Hinton PS, Haas JD (2004) Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 79(3):437–443PubMed

63.

van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8(9):485–493. doi:10.1038/nrcardio.2011.77 PubMedCrossRef

64.

Maeder MT, Khammy O, dos Remedios C, Kaye DM (2011) Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 58(5):474–480. doi:10.1016/j.jacc.2011.01.059 PubMedCrossRef

65.

Jankowska EA, Ponikowski P (2010) Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 6(3):295–304. doi:10.1016/j.hfc.2010.03.003 PubMedCrossRef

66.

Parikh A, Natarajan S, Lipsitz SR, Katz SD (2011) Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail 4(5):599–606. doi:10.1161/CIRCHEARTFAILURE.111.960906 PubMedCrossRef

67.

Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna SM, Nuti R (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152(6):1096 e1099-1015. doi:10.1016/j.ahj.2006.08.005 CrossRef

68.

Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE (1996) A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50(5):1694–1699PubMedCrossRef

69.

Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S (2005) A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68(6):2846–2856. doi:10.1111/j.1523-1755.2005.00758.x PubMedCrossRef

70.

Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50(17):1657–1665. doi:10.1016/j.jacc.2007.07.029 PubMedCrossRef

71.

Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51(2):103–112. doi:10.1016/j.jacc.2007.09.036 PubMedCrossRef

72.

Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, Chapman CM (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48(6):1225–1227. doi:10.1016/j.jacc.2006.07.015 PubMedCrossRef

73.

Usmanov RI, Zueva EB, Silverberg DS, Shaked M (2008) Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21(2):236–242PubMed

74.

Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN (2009) Anemia in chronic heart failure. Congest Heart Fail 15(2):87–92. doi:10.1111/j.1751-7133.2009.00049.x PubMedCrossRef

75.

Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Haas JD (2003) Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr 77(2):441–448PubMed

76.

Danielson BG, Salmonson T, Derendorf H, Geisser P (1996) Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46(6):615–621PubMed

77.

Seligman PA, Dahl NV, Strobos J, Kimko HC, Schleicher RB, Jones M, Ducharme MP (2004) Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 24(5):574–583PubMedCrossRef

78.

Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J (1999) Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis Off J Nat Kidney Found 33(3):471–482CrossRef

79.

Mircescu G, Garneata L, Capusa C, Ursea N (2006) Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association 21(1):120–124. doi:10.1093/ndt/gfi087 CrossRef

80.

Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association 15(11):1827–1834

81.

Fishbane S (2003) Safety in iron management. Am J Kidney Dis Off J Nat Kidney Found 41(5 Suppl):18–26CrossRef

82.

Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65(6):2279–2289. doi:10.1111/j.1523-1755.2004.00648.x PubMedCrossRef

83.

Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR (2007) Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72(5):638–642. doi:10.1038/sj.ki.5002422 PubMedCrossRef

84.

Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N (2007) Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Cardiac Fail 13(1):14–17. doi:10.1016/j.cardfail.2006.09.007 CrossRef

85.

Yuan XM, Li W (2008) Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem 15(21):2157–2172PubMedCrossRef

86.

Sullivan JL (2004) Is stored iron safe? J Lab Clin Med 144(6):280–284. doi:10.1016/j.lab.2004.10.006 PubMedCrossRef

87.

Lee TS, Shiao MS, Pan CC, Chau LY (1999) Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 99(9):1222–1229PubMedCrossRef

88.

Facchini FS, Saylor KL (2002) Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci 967:342–351PubMedCrossRef

89.

Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY (2003) Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci 10(5):510–517. doi:10.1159/000072378 PubMedCrossRef

90.

Patt A, Horesh IR, Berger EM, Harken AH, Repine JE (1990) Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. Journal of pediatric surgery 25(2):224–227; discussion 227–228

91.

Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F (1999) The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 459(2):218–222PubMedCrossRef

92.

van Jaarsveld H, Pool GF (2002) Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 161(2):395–402PubMedCrossRef

93.

Kruszewski M (2004) The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 51(2):471–480. doi:035001471 PubMed

94.

McCord JM (1998) Iron, free radicals, and oxidative injury. Semin Hematol 35(1):5–12PubMed

95.

Gey KF (1993) Prospects for the prevention of free radical disease, regarding cancer and cardiovascular disease. Br Med Bull 49(3):679–699PubMed

96.

Corti MC, Gaziano M, Hennekens CH (1997) Iron status and risk of cardiovascular disease. Ann Epidemiol 7(1):62–68PubMedCrossRef

97.

Wardman P, Candeias LP (1996) Fenton chemistry: an introduction. Radiat Res 145(5):523–531PubMedCrossRef

98.

Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF (2003) Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107(7):1053–1058PubMedCrossRef

99.

Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Investig 97(8):1916–1923. doi:10.1172/JCI118623 PubMedCrossRef

100.

Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT (1997) Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Nat Acad Sci USA 94(26):14483–14488PubMedCrossRef

101.

Krieglstein CF, Granger DN (2001) Adhesion molecules and their role in vascular disease. Am J Hypertens 14(6 Pt 2):44S–54SPubMedCrossRef

102.

Ley K, Huo Y (2001) VCAM-1 is critical in atherosclerosis. J Clin Investig 107(10):1209–1210. doi:10.1172/JCI13005 PubMedCrossRef

103.

Quinn MT, Gauss KA (2004) Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 76(4):760–781. doi:10.1189/jlb.0404216 PubMedCrossRef

104.

Yu L, Zhen L, Dinauer MC (1997) Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 272(43):27288–27294PubMedCrossRef

105.

Taille C, El-Benna J, Lanone S, Dang MC, Ogier-Denis E, Aubier M, Boczkowski J (2004) Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J Biol Chem 279(27):28681–28688. doi:10.1074/jbc.M310661200 PubMedCrossRef

106.

Li L, Frei B (2009) Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol 29(5):732–738. doi:10.1161/ATVBAHA.108.183210 PubMedCrossRef

107.

Minqin R, Watt F, Huat BT, Halliwell B (2003) Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radical Biol Med 34(6):746–752CrossRef

108.

Thong PS, Selley M, Watt F (1996) Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol Biol (Noisy-le-grand) 42(1):103–110

109.

Minqin R, Rajendran R, Pan N, Tan BK, Ong WY, Watt F, Halliwell B (2005) The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radical Biol Med 38(9):1206–1211. doi:10.1016/j.freeradbiomed.2005.01.008 CrossRef

110.

Sullivan JL (1981) Iron and the sex difference in heart disease risk. Lancet 1(8233):1293–1294PubMedCrossRef

111.

Stone NJ, Levy RI, Fredrickson DS, Verter J (1974) Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 49(3):476–488PubMedCrossRef

112.

Sullivan JL (2003) Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J 145(2):190–194. doi:10.1067/mhj.2003.142 PubMedCrossRef

113.

Kannel WB, Hjortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85(4):447–452PubMedCrossRef

114.

Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R (1992) High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86(3):803–811PubMedCrossRef

115.

Danesh J, Appleby P (1999) Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99(7):852–854PubMedCrossRef

116.

Finch CA, Cook JD, Labbe RF, Culala M (1977) Effect of blood donation on iron stores as evaluated by serum ferritin. Blood 50(3):441–447PubMed

117.

Milman N, Kirchhoff M (1991) The influence of blood donation on iron stores assessed by serum ferritin and hemoglobin in a population survey of 1359 Danish women. Ann Hematol 63(1):27–32PubMedCrossRef

118.

Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT (1997) Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ 314(7083):793–794PubMedCrossRef

119.

Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF (1997) Possible association of a reduction in cardiovascular events with blood donation. Heart 78(2):188–193PubMed

120.

Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ (2001) Blood donations and risk of coronary heart disease in men. Circulation 103(1):52–57PubMedCrossRef

121.

Meyers DG, Jensen KC, Menitove JE (2002) A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion 42(9):1135–1139PubMedCrossRef

122.

Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW (2007) Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. J Am Med Assoc (JAMA) 297(6):603–610. doi:10.1001/jama.297.6.603 CrossRef

123.

Zacharski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech F, Amidi M, Muluk S (2000) The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 139(2 Pt 1):337–345PubMed

124.

Zheng H, Huang X, Zhang Q, Katz SD (2006) Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int 69(4):679–684. doi:10.1038/sj.ki.5000046 PubMedCrossRef

125.

Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32(Suppl 1):9–16PubMedCrossRef

126.

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 339(9):584–590. doi:10.1056/NEJM199808273390903 PubMedCrossRef

Titel: Iron deficiency anemia in heart failure
verfasst von: Natasha P. Arora
Jalal K. Ghali
Publikationsdatum: 01.07.2013
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 4/2013
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-012-9342-y

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Iron deficiency anemia in heart failure

Abstract

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Determinants of adherence to heart failure medication: a systematic literature review

Peripheral arterial disease and chronic heart failure: a dangerous mix

Treatment for chronic heart failure in the elderly: current practice and problems

Can parathyroid hormone be used as a biomarker for heart failure?

Analyzing left ventricular function in mice with Doppler echocardiography

The ryanodine receptor leak: how a tattered receptor plunges the failing heart into crisis

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie